Open Access Library Journal

Volume 5, Issue 10 (October 2018)

ISSN Print: 2333-9705   ISSN Online: 2333-9721

Google-based Impact Factor: 0.47  Citations  

Efficacy of a Combination of Tanacetum parthenium, 5-Hydroxy Tryptophan and Magnesium (Aurastop) in the Prevention of High Frequency Migraine with Aura

HTML  XML Download Download as PDF (Size: 548KB)  PP. 1-8  
DOI: 10.4236/oalib.1104939    202 Downloads   335 Views  

ABSTRACT

Object: To verify the efficacy and safety of the new combination of Tanacetum parthenium 150 mg, 5-hydrossitriptophan (5-HTTP) 20 mg and magnesium 185 mg (Aurastop) in the prophylactic treatment of high frequency migraine with aura (MWA). According to the international headache classification (IHCD 3 beta version) the aura phenomena have a duration of 5 - 60 minutes for any of the usual disturbances (visual, somatosensory and speech disturbance) but no classification describes the frequency of this phenomena. Patients who experience migraine aura emphasize the emotional impact of such a phenomenon, mostly because of the severe, though transient, disability caused by the aura symptoms (i.e., inability to work or driving a vehicle). Furthermore, a profound asthenia lasts for about 48 hours after the resolution of the painful phase. Materials and Method: 18 patients (F: n = 10, M: n = 8, mean age: 28) presenting with an ICHD-3 beta diagnosis of migraine with aura (MWA) with a frequency of more than 5 attacks of migraine with aura per month since at least 6 months, were enrolled in the survey and treated with Aurastop? twice a day for a period of 3 months. Diary cards were filled in during a 3-month period before the beginning of the survey and during the 3-month duration of the study. The reduction of MWA attacks per month was assessed as the primary end-point; the reduction of the duration and disability of the aura and of the intensity of the headache were considered as secondary end-points. Results: A statistically significant reduction of MWA attacks/month was observed: more than 95% of the patients referred a reduction >50% of the frequency, 66.6% a reduction of more than 70%, and 16.6% a complete disappearance of the attacks after the first week of therapy. Moreover, a sensible reduction of the duration and disability of the aura phenomena was reported by more than 90% of the patients and, in the 55% of the patients also a reduction of the intensity of the headache. No side effects were reported. The efficacy started to appear during the first month of intake and was maintained during the three months of therapy.

Cite this paper

Volta, G. , Zavarise, P. , Perego, L. and Pezzini, A. (2018) Efficacy of a Combination of Tanacetum parthenium, 5-Hydroxy Tryptophan and Magnesium (Aurastop) in the Prevention of High Frequency Migraine with Aura. Open Access Library Journal, 5, 1-8. doi: 10.4236/oalib.1104939.

Cited by

No relevant information.

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.